Highest development stage: Phase 3 prepared

Development status: Active (as of 2022)

Gram-negative activity

Mechanism of Action/Target pathogen: Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis. Carbapenems bind to all PBPs, with PBP2 and PBP4 as the highest-affinity targets

Additional information: Semisynthetic, derived from thienamycin, similar to ertapenem. Developed in and for China